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Novelty and Impact: Positive associations between blood concentrations of the inflammatory 
marker C-reactive protein (CRP) and risk of colorectal cancer have been observed in several 
large prospective studies, but these observations may be influenced by bias and it is unknown 
whether they reflect a causal relationship. We observed that genetically determined higher CRP 
concentrations were associated with higher risk of colorectal cancer, supporting the hypothesis 
that elevated CRP is directly involved in colorectal carcinogenesis. 
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ABSTRACT 
High blood concentrations of C-reactive protein (CRP) have been associated with elevated risk of 
colorectal cancer in several prospective studies including the European Prospective Investigation 
into Cancer and Nutrition (EPIC), but it is unknown whether these observations reflect a causal 
relationship. We aimed to investigate whether CRP genetic variants associated with lifelong 
higher CRP concentrations translate into higher colorectal cancer risk. We conducted a 
prospective nested case-control study within EPIC including 727 cases diagnosed between 1992 
and 2003 and 727 matched controls selected according to an incidence-density sampling protocol. 
Baseline CRP concentrations were measured in plasma samples by a high sensitivity assay. 
Tagging single nucleotide polymorphisms (SNPs) in the CRP gene (rs1205, rs1800947, 
rs1130864, rs2808630, rs3093077) were identified via HapMap.  The causal effect of CRP on 
colorectal cancer risk was examined in a Mendelian Randomization approach utilizing multiple 
CRP genetic variants as instrumental variables. The SNPs rs1205, rs1800947, rs1130864 and 
rs3093077 were significantly associated with CRP concentrations and were incorporated in a 
CRP allele score which was associated with 13% higher CRP concentrations per allele count 
(95% confidence interval 8%, 19%). Using the CRP-score as instrumental variable, genetically 2-
fold higher CRP concentrations were associated with higher risk of colorectal cancer (odds ratio 
1.74, 95% confidence interval 1.06, 2.85). Similar observations were made using alternative 
definitions of instrumental variables. Our findings give support to the hypothesis that elevated 
circulating CRP may play a direct role in the etiology of colorectal cancer.  
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INTRODUCTION 
High blood concentrations of the inflammatory marker C-reactive protein (CRP) have been 
associated with moderately elevated risk of colorectal cancer in several prospective studies1. 
Recent data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study 
showed a positive association between circulating CRP and risk of colon but not rectal cancer, 
and that the association with colon cancer was independent of a variety of metabolic factors 
including body mass index (BMI), waist circumference, elevated glycated hemoglobin (HbA1c), 
elevated C-peptide and reduced high density lipoprotein cholesterol (HDL-C) 2. However, 
findings from observational studies relating circulating CRP to risk of colorectal cancer are prone 
to bias by reverse causation due to inflammatory processes that can originate from occult cancer. 
Furthermore, CRP concentrations are influenced by a variety of life-style factors such as 
obesity 3, physical activity 4 and diet 5, that could also influence colorectal cancer risk. Thus, even 
after adjustment for various potentially confounding factors, as was done in the study in EPIC 2, 
residual confounding factors may still distort findings. Hence, from standard observational 
studies it cannot necessarily be assumed that elevated CRP is directly involved in colorectal 
carcinogenesis. Mendelian Randomization (MR) is an approach to elucidate whether intermediate 
modifiable traits such as biomarker concentrations are causally related to disease risk. Under the 
assumption of the random assortment of alleles at gamete formation, genetic variants associated 
with biomarker levels can be used as relatively unbiased proxies for biomarker concentrations 
because they are generally unrelated to confounding factors that typically distort findings from 
conventional epidemiological studies 6 and they cannot be altered by disease occurrence, thereby 
circumventing reverse causation. The aim of our study was to investigate whether CRP genetic 
variants associated with lifelong differences in CRP concentrations translate into differences in 
colorectal cancer risk. We first estimated the association of those genetic variants with colorectal 
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cancer risk and then performed a formal MR approach by instrumental variable analysis to 
examine the causal association between elevated CRP concentrations and colorectal cancer risk. 
 
METHODS 
Study population 
This study was conducted using a nested case-control design within the European Prospective 
Investigation into Cancer and Nutrition (EPIC), a large prospective cohort with more than 520 
000 participants from 10 countries, aged 25-70 years at recruitment between 1992 and 20007. All 
participants gave written informed consent. At recruitment, anthropometric measurements and 
blood samples were taken and the participants completed questionnaires on medical history, 
medication, sociodemographic and lifestyle characteristics7-9. The EPIC study was approved by 
the ethics review board of the International Agency for Research on Cancer (Lyon, France) and 
the local review boards of the participating institutions. 
Follow-up procedures 
Incident cancer cases were identified through record linkage with regional cancer registries at all 
study centers except those in Germany, France, Greece, and Naples (Italy), where active follow-
up using a combination of methods, including health insurance records, cancer and pathology 
registries, and direct contact of participants or next-of-kin, was used. For the present study, the 
closure dates, defined as the latest date of complete follow-up for both cancer incidence and vital 
status, ranged from December 1999 to June 2003 for study centers using registry data, and from 
June 2000 to December 2002 for study centers using active follow-up methods. 
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Nested case-control study  
Colorectal cancer was defined based on the International Statistical Classification of Diseases, 
Injury and Causes of Death (10th Revision) as a combination of tumors of the colon (C18.0-
C18.7), tumors that were overlapping or unspecified (C18.8-C18.9), and tumors of the rectum 
(C19- C20). For location-specific analyses, overlapping and unspecified tumors were grouped 
among all colon cancers (C18:0–C18:9). A total of 727 incident cases of colorectal cancer (483 
colon, 244 rectal) with available blood samples and DNA were included in the present study. 
This number differs from the study on CRP levels and risk of colorectal cancer (1096 cases) 2 in 
EPIC, because DNA samples from Denmark were unavailable due to local technical and 
organizational issues that delayed sample retrieval. Using risk set sampling, for each case one 
control was randomly selected among participants free of cancer at the time of diagnosis of the 
index case, matched on sex, age at blood collection (2-months to 4-year intervals), study center, 
and fasting status (<3, 3-6, or >6 hours). Women were additionally matched on menopausal 
status (premenopausal, perimenopausal, postmenopausal, or surgically menopausal). 
Premenopausal women were matched on phase of the menstrual cycle at blood collection (early 
follicular, late follicular, ovulatory, early luteal, mid-luteal, or late luteal), and postmenopausal 
women were matched on current use of hormone replacement therapy (yes/no). The latter 
matching criteria were used because the nested case-control study was designed to be used for 
several biomarker studies, including studies on hormonal factors in relation to colorectal cancer 
risk.  
Tagging SNP selection and genotyping procedures 
A set of tagging single nucleotide polymorphisms (SNPs) was selected to cover variations in the 
CRP gene common to populations of European descent. The tagging SNPs  were selected via 
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HapMap 22/phaseII CEPH (Utah residents with ancestry from northern and western Europe) 
population data  applying stringent criteria (minor allele frequency >5% and pairwise r2≥0.80), 
according to Tagger software10 implemented in the Haploview program 11 and from a genome-
wide association study 12. The final list of selected tagging SNPs was: rs1205 (C>T, 3’ 
untranslated region), rs2794520 (C>T, 3’ flanking region), rs1800947 (C>G, exon 2), rs1130864 
(G>A, 3’ untranslated region), rs2808630 (T>C, 3’ untranslated region), rs2794521 (T>C, 5’ 
flanking region), rs3093077 (A>C, 3’ untranslated region). Some of the selected SNPs have also 
been identified in more recently published genome-wide association studies on CRP-levels 12-14. 
All SNPs have been previously associated with circulating CRP concentrations in 
epidemiological studies13, 15-17. The selected SNPs were genotyped using TaqMan methodology. 
Genotype call rates were >99.2% for all assays. Of the genotyped SNPs, rs2794520 was in high 
agreement (kappa=0.99) and linkage disequilibrium (r2≥0.80) with rs1205 and rs2794521 was in 
high agreement with rs2808630 (kappa=0.99). We omitted rs2794520 and rs2794521 from 
analysis. We assumed an additive genetic model for all CRP-SNP genotypes. Due to the very low 
number of homozygote variant genotypes in rs1800947 (n=8 with GG genotype) and rs2808630 
(n=4 with CC genotype), for these two SNPs the homozygote variants were grouped together 
with heterozygotes for categorical analyses. 
 
Laboratory analyses 
Plasma CRP was measured using a high sensitivity assay (Beckman-Coulter, Woerden, the 
Netherlands) as described previously2.  
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Circulating levels of C-peptide, HbA1c, insulin-like growth factor 1 (IGF-1), total cholesterol, 
triglycerides, HDL-C, low density lipoprotein cholesterol (LDL-C), total and high-molecular 
weight adiponectin, leptin, soluble leptin receptor (sOB-R), and 25-hydroxy vitamin D have been 
determined within separate research projects in the same nested case-control study as described 
previously 18-21.  
 
Statistical analysis 
Hardy-Weinberg Equilibrium was tested in control participants using the Chi-Squared test. 
Baseline characteristics between cases and controls and between SNP genotypes (among 
controls) were compared using paired t-test, Wilcoxon signed rank test, or Mc Nemar’s test. 
CRP-values were naturally log-transformed.    
To verify whether selected SNPs can be utilized as instrumental variables for MR analysis, the 
association between selected SNPs and CRP concentrations was quantified using linear 
regression models with robust variance  in controls. Geometric mean CRP concentrations and 
95% confidence intervals (95% CI) by genotype and the estimated percent difference in CRP 
levels per minor allele (with genotypes coded 0, 1 or 2 according to the number of minor alleles) 
are presented. We created an unweighted CRP-score by counting the alleles of the CRP SNPs 
that were individually associated with higher CRP concentrations. In addition, a weighted allele 
score was created by summing each genotype multiplied by its estimated coefficient from the 
linear regression, divided by the sum of weights22. The weighted CRP-score was divided in 
tertiles for categorical analyses. 
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Using the expectation-maximation algorithm, haplotype frequencies were estimated from the 
SNPs rs1800947, rs1130864, rs1205, rs2808630 and rs3093077 (JMP Genomics/SAS 9.3). 
Haplotypes with a frequency lower than 5% were pooled 23. Haplotype-specific differences in 
CRP concentrations were estimated among controls using an additive model with the haplotype 
associated with the highest CRP concentration as reference. 
To explore whether individual SNPs, CRP-scores and CRP haplotypes are associated with risk of 
colorectal, colon or rectal cancer, we used conditional logistic regression models controlling for 
matching variables to estimate odds ratios (OR) that can be interpreted as incidence rate ratios. 
Sex-specific associations are shown for colorectal cancer, but due to limited sample size, sex-
specific associations for colon and rectal cancer are not shown. We also investigated whether 
adjustment for covariates including smoking, education, alcohol consumption, dietary intake and 
physical activity influenced the risk estimates. In addition, we examined whether ORs were 
different after additional adjustment for measured CRP. 
Finally, in a formal MR approach, the causal effect of low-grade inflammation reflected by CRP 
on colorectal cancer risk was quantified by instrumental variable analysis using two-stage least 
squares regression adjusted for matching factors. The first stage comprised the linear regression 
of log-transformed CRP concentrations on the genetic instrument, resulting in predicted values of 
CRP concentrations. The second stage comprised a logistic regression of colorectal cancer on the 
predicted CRP concentrations. Instrument strength for MR analysis was evaluated using the F-
statistic24 from the first stage regression. An F-value >10 is considered the minimally required 
instrument strength 24 for unbiased instrumental variable estimation 25. We used different 
definitions of instrumental variables to explore the robustness of associations. To compare the 
association between genetically raised CRP (instrumental variable analysis) and measured CRP 
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in relation to colorectal cancer, we also present the multivariable adjusted ORs from the 
conditional logistic regression analysis for the association between measured CRP concentration 
and risk of colorectal cancer in the previously used dataset with 1096 case-control pairs 
(previously published with slightly different adjustment) 2, as well as in our data set of 727 case-
control pairs. As a sensitivity analysis and to produce results comparable with two recently 
published MR studies on CRP and cancer26, 27, we also conducted a MR analysis using probit 
models. Interpretation of coefficients from probit models is less intuitive than odds ratios from 
logistic regression approaches. In brief, coefficients from probit regression models indicate the 
estimated change in the probability of the outcome for a one unit change of the exposure. We 
computed probit coefficients using standard (measured CRP, multivariable adjusted for matching 
factors and covariables) and instrumental variable (adjusted for matching factors) probit 
regression. All reported p-values are two-sided. Instrumental variable analyses were performed 
using the STATA, Version 12.1 (StataCorp, College Station, Texas, USA). All other analyses 
were performed using SAS Enterprise Guide, Version 4.3 (SAS Institute Inc., Cary, North 
Carolina, USA). 
 
RESULTS 
Genotype frequencies of all CRP-SNPs were consistent with Hardy-Weinberg equilibrium (data 
not shown). Colorectal cancer cases had a higher BMI and waist circumference than controls, 
were more often physically inactive and had a higher intake of alcohol, total energy and red and 
processed meat (Table 1). Compared to controls, cases had lower concentrations of total 
cholesterol, LDL-C, HDL-C, adiponectin, sOB-R and 25-hydroxy vitamin D. None of the 
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potentially confounding lifestyle, dietary or metabolic factors differed substantially across CRP-
SNP genotypes or the CRP-score values (supplemental table 1).  
Association between genotype and circulating CRP  
The SNPs rs1205 and rs1800947 were associated with lower CRP concentrations per minor 
allele, while the minor alleles of rs1130864 and rs3093077 were associated with higher CRP 
concentrations (Table 2). rs2808630 was not associated with CRP. The CRP-score was created 
by counting the alleles associated with higher CRP concentrations, i.e. the C-alleles of rs1205, 
rs1800947, and rs3093077, and the A-allele of rs1130864. Each allele count of the unweighted 
CRP-score was associated with 13% higher CRP, explaining 2% of inter-individual variation in 
CRP concentrations. The weighted CRP-score was associated with 29% higher CRP per score 
unit and explained 3% of inter-individual variation. 
Five CRP haplotypes with a frequency >5% were identified. The haplotype C-G-C-T-C was 
associated with 128% higher CRP concentrations than haplotype G-G-T-T-A (Supplemental 
Table 2). 
Association between genetic variation in the CRP gene and risk of colorectal cancer 
The T-allele of rs1205, which was associated with 19% lower CRP, was also associated with 
lower risk of colorectal cancer (p-trend 0.01) (Table 3). The A-allele of rs11308864, which was 
associated with 15% higher CRP, was associated with higher risk of colorectal cancer overall (p-
trend 0.04) and in women (p-trend 0.04), but not in men. SNPs rs1800947, rs3093077 and 
rs2808630 were not associated with colorectal cancer risk. Both the unweighted and weighted 
CRP-scores were positively associated with risk of colorectal and colon cancer and less 
pronounced with risk of rectal cancer. None of the observed associations was considerably 
13 
 
influenced by adjustment for potentially confounding factors such as education, physical activity, 
smoking status, alcohol or red and processed meat intake (data not shown). Associations were 
only weakly attenuated by adjustment for measured CRP concentrations. For example, the 
highest versus lowest category in the unweighted CRP-score was associated with an OR of 
colorectal cancer of 1.50 (95% CI 1.01-2.22, p-trend 0.02) before and an OR of 1.45 (95% CI 
0.97-2.15, p-trend 0.07) after adjustment for log-transformed CRP concentration. With the 
haplotype C-G-C-T-C as reference, none of the identified common haplotypes was clearly 
associated with risk of colorectal, colon or rectal cancer (supplemental Table 3). 
Association between circulating CRP and risk of colorectal cancer 
In multivariable adjusted conditional logistic regression models, two-fold higher circulating CRP 
concentration was associated with a moderately higher risk of colorectal cancer (OR 1.06, 95% 
CI 1.00-1.13) in the full dataset (1096 case-control pairs) (Figure 1). The association was similar 
in the present dataset of 727 case-control pairs (OR 1.04, 95% CI 0.97, 1.12).  
Associations between CRP and risk of colorectal cancer by using instrumental variables 
Using the unweighted CRP-score as instrumental variable, genetically 2-fold higher CRP was 
associated with 74% higher (95% CI 1.06, 2.85) risk of colorectal cancer (Figure 1). With the 
weighted CRP-score as instrumental variable, 2-fold higher CRP was associated with 57% higher 
risk of colorectal cancer (95% CI 0.99, 2.48). A 48% higher risk of colorectal cancer (95% CI 
0.94, 2.32) was observed when using CRP haplotypes as instrumental variables. Using rs1205 (F-
value 21.6) as instrumental variable, genetically higher CRP was associated with significantly 
higher risk of colorectal cancer. SNPs rs1800947, rs1130864, and rs3093077 were of weaker 
instrument strength (F-values <15), resulting in wider confidence intervals for MR estimates. 
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Genetically raised CRP through rs1130864 was significantly associated with higher risk of 
colorectal cancer, while no association was observed with rs1800947 as instrumental variable and 
-contrary to the expected-  a lower risk of colorectal cancer was observed using rs3093077 as 
instrumental variable. Using the unweighted or weighted CRP-score as instrumental variables, 
genetically raised CRP was positively associated with colorectal cancer risk in both men and 
women, as well as with colon and rectal cancer, although confidence intervals were wide for 
these subgroup analyses (supplemental figure 1).  
Associations between CRP and risk of colorectal cancer by using standard and 
instrumental variable probit regression 
In standard probit analysis multivariable adjusted for matching factors and covariables, a one-unit 
increase in log-transformed CRP was associated with a statistically significantly higher 
probability of colorectal cancer (beta 0.07, 95% CI 0.01, 0.13). In the instrumental variable probit 
analysis, significant associations between genetically raised CRP and risk of colorectal cancer 
were observed with the unweighted CRP-score (beta 0.40, 95% CI 0.09, 0.72), rs1205 (beta 0.56, 
95% CI 0.25, 0.88) and rs1130864 (beta 0.57, 95% CI 0.18, 0.96) as instrumental variables. 
DISCUSSION 
In this study, we observed that the CRP SNPs rs1205 and rs1130864 were significantly 
associated with risk of colorectal cancer in the direction expected from their association with 
CRP concentrations. In a formal MR approach using multiple genetic variants of the CRP gene 
and a set of alternative instrumental variable definitions, we observed that genetically raised CRP 
concentrations were associated with higher risk of colorectal cancer, with significant MR 
estimates for the unweighted CRP-score, rs1205 and rs1130864 as instrumental variables. These 
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findings give support to the hypothesis that elevated CRP is directly involved in colorectal 
carcinogenesis.  
There is strong evidence for inflammatory processes playing a role in the development of 
colorectal cancer 28, which is convincingly supported by the observed association between local 
inflammation of the colorectal mucosa due to inflammatory bowel disease and colorectal cancer 
risk 29, 30. Furthermore, there is evidence that reduction of systemic inflammation induced by 
weight loss also has tissue-specific consequences, i.e. reduced inflammation in the colorectal 
mucosa 31. However, as to date no specific mechanism has been suggested to explain how 
elevated circulating CRP could directly influence colorectal carcinogenesis 32 and experimental 
studies on the direct effect of CRP on colorectal cancer cells are scarce.  Furthermore, studies 
investigating whether genetic variation in the CRP gene is associated with inflammatory and/or 
carcinogenic processes beyond CRP concentrations are scarce. There is some suggestion that 
CRP itself exerts proinflammatory effects33, although in a recent study the inflammatory status of 
random colonic biopsies was largely unrelated to circulating CRP34. On the other hand, it has 
been shown that CRP induces the expression of adhesion cells, which is an important step in 
tumorigenesis 35 and could serve as an alternative causal process.  
Standard epidemiological studies relating blood concentrations of CRP to risk of colorectal 
cancer have not always been consistent. As to date, 7 out of 15 prospective studies published 
between 2003 and 2012 observed significant positive associations between circulating CRP and 
risk of colorectal cancer 36, 37. In a meta-analysis from 2008, CRP concentrations were positively 
associated with risk of colorectal cancer, with stronger associations for colon than for rectal 
cancer and stronger associations in men than in women 1. In the most recent and so far largest 
study in women, the Women’s Health Initiative Observational Study, a modest positive 
association between baseline CRP concentrations and colorectal cancer risk was observed 36.  
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We are aware of three MR studies investigating the potentially causal association between CRP 
concentrations and risk of colorectal cancer26, 27, 38. In the first study, common genotype 
combinations of 4 CRP-SNPs (rs1205, rs1130864, rs3093077, and rs3091244) were associated 
with up to 72% higher CRP concentrations, but not with higher risk of colorectal cancer (197 
cases) 38. In the second study using a CRP-score from two CRP-associated SNPs (rs2794520 of 
the CRP gene and rs1169300 of the HNF1A  gene) in an instrumental variable probit model, a 
non-significantly higher probability of colorectal cancer (116 cases, beta per one unit in log-
transformed CRP 0.07, 95% CI -0.44, 0.58) was observed 26. The third and most recently 
published MR study on the association between CRP and risk of cancer is in line with our 
findings27: In this study a weighted score of 20 CRP-related SNPs located in or near 20 genes 
including CRP, APOC1, HNF1A, and LEPR was significantly associated with risk of colorectal 
cancer in instrumented probit analysis (105 cases, beta per one unit in log-transformed CRP 0.44, 
95% CI 0.12, 0.75). Similar to our observations, the coefficient from standard probit analysis was 
substantially weaker (beta 0.08, 95% CI -0.003, 0.17) than the instrumental variable probit 
coefficient. Studies that related CRP genetic variation to risk of colorectal cancer without a 
formal MR approach have not always been consistent39-41. While in the so far largest study SNPs 
in the CRP gene including rs1205 were significantly associated with risk of colon cancer (1,574 
cases) 40,  the SNPs rs1205 and rs1130864 (which were significantly associated with colorectal 
cancer risk in our study) were not individually associated with risk of colorectal cancer in the 
Rotterdam Study (189 cases)39 and the CLUE II cohort (208 cases)41. In CLUE II, however, two 
CRP haplotypes were significantly associated with colorectal cancer risk41.    
Given that our MR study gives support to elevated CRP playing a causal role in the etiology of 
colorectal cancer, the critical evaluation of the MR assumptions for the instrumental variables 
approach 42 is particularly important. In our setting, the three assumptions for instrumental 
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variables were: (1) instrumental variable is associated with CRP concentrations, (2) it is 
independent of factors that may confound the association between CRP and colorectal cancer, 
and (3) it is associated with colorectal cancer only through CRP (no pleiotropy, i.e. genetic 
variants having multiple functions). Regarding the first assumption, four CRP SNPs included in 
our study were significantly associated with CRP concentrations, and all but two (CRP 
haplotypes and rs3903077) instrumental variables had F-values >12, thereby not falling below 
the “weak instruments” threshold (F-value <10) that is typically applied in MR studies 24.  Weak 
instrumental variables may produce biased effect estimates when there is confounding in the 
exposure-disease relationship25, but the size of bias is inversely related to the F-value 43.  
Therefore, the MR estimates based on the CRP-score (F-value >35) can be considered more 
reliable than the MR estimates based on rs3903077 (F-value 9.1) or the CRP haplotypes (F-value 
8.1). In terms of the second MR assumption, as expected given the random assortment of alleles 
at conception, none of the potentially confounding factors varied substantially across CRP SNP 
genotypes or the CRP scores, suggesting that the second assumption is fulfilled. Regarding the 
third MR assumption, various potentially mediating metabolic factors including C-peptide, 
HbA1c, and adipokines did not vary across genotypes, arguing against pleiotropic effects 
invalidating the MR approach 42. Furthermore, the risk of unknown pleiotropy is reduced by 
using multiple genetic instruments 42. The risk of pleiotropy would have been even lower, if 
CRP-associated SNPs from different genes would have been taken into account27. Although 
CRP-associated SNPs in other genes were not available in the present study, our approach of 
including only genetic variants located in the CRP gene yielded similar results as in the study by 
Prizment et al 27, in which CRP-associated SNPs located in or near 20 different genes were 
utilized. Nevertheless, we found little attenuation of the association between CRP genetic 
variation and colorectal cancer risk after additional adjustment for measured CRP concentrations, 
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indicating that the third assumption, also referred to as exclusion restriction assumption 44, may 
be violated. While the weak attenuation may simply reflect measurement error in the one-time 
measured CRP concentrations, a violation of the exclusion restriction assumption may result in 
biased MR estimates and thus we cannot exclude that the instrumental-variable odds ratios 
overestimated the true association43, 44.  
Our study has some limitations such as the modest sample size leading to wide confidence 
intervals. Therefore, replication in a larger study is desirable. Especially the systematic 
examination of potentially differential associations by site and sex will only be feasible in larger 
settings. MR analysis using genetic instruments with two-stage least squares regression can be 
biased when both the variance explained by the instruments and the sample size are small 45. 
Even though our sample size was limited, the CRP-scores had F-values >35 and explained 2-3% 
of the inter-individual variance in CRP concentrations. However, we cannot exclude that the 
association between CRP genetic variation and risk of colorectal cancer is due to chance. It is 
also a limitation of our study is that we were not able to verify whether CRP or CRP genetic 
variation was associated with other biomarkers of inflammation and/or colonic inflammation. 
Furthermore, it should be noted that we cannot exclude that the here employed CRP SNPs are in 
linkage disequilibrium with other genetic markers that are associated with colorectal cancer risk 
via a CRP-independent pathway. Population stratification may have confounded our MR 
estimates, but given the relatively homogenous European study population and the use of 
multiple genetic variants as instrumental variables this source of bias is rather unlikely42. In 
general, potential bias by geographical differences and/or differential follow-up procedures (e.g. 
active follow-up versus registry data) is likely small in this nested case-control study, because 
both cases and controls originate from the same source population with the same geographical 
background and center-specific follow-up procedures and were matched by study center (in 
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addition to other matching factors). Nevertheless, the selected control group may not be fully 
representative to the source population, since per each case one control participant was selected 
based on matching criteria. However, this mainly results in a loss of precision of risk estimates, 
and potential bias is likely to be small and expected to be random.46  
CONCLUSION 
This MR study utilizing multiple genetic variants of the CRP-gene as instrumental variables 
gives support to the hypothesis that elevated CRP is directly involved in colorectal 
carcinogenesis. Given the modest sample size, the results require cautious interpretation, 
particularly when referring to sex-specific analyses and subtypes of colorectal cancer. Our 
findings warrant confirmation by larger MR studies and experimental studies investigating a 
potential mechanism of action for CRP as a direct contributor to colorectal carcinogenesis.  
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Figure 1. Estimates of the association of circulating (observational) and genetically raised 
(instrumental variable analysis) CRP levels with risk of colorectal cancer 
* OR per 2-fold higher CRP concentration on the original scale corresponds to a difference in 
log-transformed CRP concentrations of log 2. 
† Observational OR (95% CI) from conditional logistic regression adjusted for smoking status 
(never, former, current or missing data), education (no school degree/primary school, 
technical/professional school, secondary school, university degree, or missing data), alcohol 
consumption (nondrinker or g/day), and physical activity (inactive, moderately inactive, 
moderately active, active, or missing data), body mass index and waist circumference 
‡ Instrumental variable analysis by 2-stage least-squares regression, adjusted for matching factors 
F-values (indicator of instrument strength) derived from first-stage regression.  
rs2808630 not displayed because of insufficient instrument strength (F-value=0.46) 
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Table 1. Baseline characteristics of incident colorectal cancer cases and matched controls 
(n=1,454)   
  Controls (n=727) Cases (n=727) p-value 
Female sex, n (%) 396 (54.5) 396 (54.5) * 
Age, years, mean (SD) 58.9 (7.9) 59.0 (7.9) * 
Current smoking, n (%) 150 (20.6) 138 (19.0) 0.41 
University degree, n (%) 119 (16.4) 115 (15.8) 0.76 
Physically inactive, n (%) 75 (10.3) 101 (13.9) 0.02 
Height, cm, mean (SD) 166 (8.9) 167 (9.2) 0.02 
Body mass index, kg/m2, mean (SD) 26.4 (3.8) 27.1 (4.3) 0.002 
Waist circumference, cm, mean (SD) 88.6 (11.9) 90.6 (13.1) 0.0002 
Alcohol intake, g/day, median (IQR) 5.84 (0.89-16.10) 6.15 (0.76-19.89) 0.11 
Fiber, g/day, median (IQR) 21.89 (17.74-26.82) 21.76 (17.16-27.38) 0.73 
Energy, kcal/day, median (IQR) 1952 (1608- 2401) 2051 (1641- 2490) 0.05 
Fruits and vegetables, g/day, median (IQR) 397.1 (259.7-566.2) 383.2 (258.9-553.6) 0.58 
Red and processed meat, g/day, median (IQR) 69.81 (45.22-102.4) 71.99 (46.55-106.5) 0.28 
Fish, g/day, median (IQR) 21.91 (10.19-39.64) 20.29 (9.86-35.74) 0.21 
CRP, mg/L, median (IQR) 2.25 (1.07- 4.36) 2.86 (1.12- 5.20) 0.01 
C-peptide (ng/mL), median (IQR) 3.50 (2.68- 5.09) 3.75 (2.80- 5.31) 0.29 
HbA1c (%), median (IQR) 5.70 (5.50- 6.00) 5.80 (5.50- 6.10) 0.18 
IGF1 (ng/mL), median (IQR) 211.9 (170.5-262.7) 214.4 (170.5-262.2) 0.80 
Total cholesterol (mmol/L), median (IQR) 6.39 (5.60- 7.19) 6.21 (5.49- 6.94) 0.02 
LDL cholesterol (mmol/L), median (IQR) 4.35 (3.70- 5.16) 4.23 (3.58- 4.87) 0.02 
HDL cholesterol (mmol/L), median (IQR) 1.34 (1.14- 1.61) 1.31 (1.08- 1.58) 0.004 
Triglycerides (mmol/L), median (IQR) 1.40 (0.96- 2.00) 1.41 (0.97- 2.10) 0.22 
Total adiponectin (μg/mL), median (IQR) 6.59 (4.90- 9.01) 6.16 (4.48- 8.51) 0.002 
HMW adiponectin (µg/mL), median (IQR) 3.30 (2.14- 4.99) 3.27 (2.01- 4.83) 0.31 
Leptin (ng/mL), median (IQR) 9.25 (4.29-19.80) 9.59 (4.76-18.20) 0.41 
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Soluble Leptin Receptor (ng/mL), median (IQR) 21.40 (17.60-26.40) 20.20 (16.30-24.50) <0.0001 
25-hydroxy vitamin D (nmol/L), median (IQR) 59.20 (44.30-78.00) 55.65 (39.90-71.90) 0.001 
 
SD, standard deviation, IQR, inter-quartile range, HMW, high-molecular weight    
P-values for the difference between cases and controls were determined by Mc Nemar's test for 
variables expressed as %, by student's paired t-test for variables expressed as means, and by 
Wilcoxon’s signed rank test for variables expressed as medians    
* matching variable   
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Table 2. Association between CRP polymorphisms, CRP-genetic score and CRP concentration 
among controls (n=727) 
SNP MAF n Mean (95% CI), mg/L 
rs1205a 0.34     
CC  
 
302 2.47 (2.20; 2.77) 
CT  
 
342 2.04 (1.81; 2.29) 
TT 
 
81 1.71 (1.39; 2.10) 
p-trend 
  
0.001 
Percent difference in CRP per T-allele -19% (-30%; -8%) 
rs1800947a 0.07 
  CC 
 
633 2.24 (2.07; 2.44) 
CG/GG 
 
93 1.68 (1.37; 2.06) 
p-trend 
  
0.004 
Percent difference in CRP per G-allele -30% (-51%; -10%) 
rs1130864a 0.31 
  GG 
 
346 2.01 (1.80; 2.25) 
GA 
 
317 2.20 (1.96; 2.48) 
AA 
 
62 2.91 (2.30; 3.67) 
p-trend 
  
0.01 
Percent difference in CRP per A-allele 15% (3%; 26%) 
rs2808630 0.27 
 
 
TT 
 
386 2.28 (2.05; 2.53) 
CT 
 
279 1.94 (1.71; 2.19) 
CC 
 
58 2.60 (1.96; 3.44) 
p-trend 
  
0.61 
Percent difference in CRP per C-allele -3% (-15%; 9%) 
rs3093077a 0.07 
  AA 
 
621 2.06 (1.89; 2.24) 
30 
 
AC/CC 
 
101 2.91 (2.40; 3.53) 
p-trend 
  
0.002 
Percent difference in CRP per C-allele 32% (12%; 53%) 
Unweighted CRP-
score 
   0 or 1 
 
24 1.47 (0.98; 2.20) 
2 
 
80 1.69 (1.39; 2.06) 
3 
 
157 1.79 (1.51; 2.12) 
4 
 
222 2.41 (2.09; 2.79) 
5 
 
153 2.19 (1.86; 2.58) 
6 or 7  
 
90 3.05 (2.54; 3.67) 
p-trend 
  
<0.0001 
Percent difference in CRP per 
score unit  13% (8%; 19%) 
Weighted CRP-score   
Tertile 1 261 1.73 (1.53; 1.96) 
Tertile 2 190 2.25 (1.92; 2.64) 
Tertile 3 275 2.59 (2.30; 2.92) 
p-trend  <0.0001 
Percent difference in CRP per score 
unit 
 29% (18%; 40%) 
MAF=Minor allele frequency in controls, CRP, C-reactive protein 
a incorporated in CRP-score   
Models were unadjusted.  
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 Table 3. Association between CRP genetic variation and risk of colorectal cancer (n=1,454) 
 
CRP 
genotype 
  % 
difference 
in CRPa 
Colorectal cancer Men Women Colon cancer Rectal cancer 
Ca/Co OR (95% CI) Ca/Co OR (95% CI) Ca/Co OR (95% CI) Ca/Co OR (95% CI) Ca/Co OR (95% CI) 
rs1205                 
CC 0 358/302 1.00 (Ref.) 161/129 1.00 (Ref.) 197/173 1.00 (Ref.) 241/201 1.00 (Ref.) 117/101 1.00 (Ref.) 
CT -21 292/342 0.74 (0.60-0.92) 131/165 0.64 (0.46-0.89) 161/177 0.83 (0.62-1.10) 201/227 0.75 (0.58-0.98) 91/115 0.71 (0.49-1.04) 
TT -44 71/81 0.76 (0.53-1.08) 37/35 0.84 (0.50-1.41) 34/46 0.67 (0.41-1.10) 38/54 0.59 (0.37-0.93) 33/27 1.11 (0.63-1.97) 
p-trend    0.01   0.09   0.07   0.01   0.60 
per T allele -19  0.82 (0.70-0.96)  0.82 (0.65-1.03)  0.82 (0.67-1.01)  0.76 (0.63-0.93)  0.93 (0.72-1.21) 
rs1800947                 
CC 0 636/633 1.00 (Ref.) 289/286 1.00 (Ref.) 347/347 1.00 (Ref.) 426/429 1.00 (Ref.) 210/204 1.00 (Ref.) 
CG/GG -35 84/93 0.91 (0.67-1.23) 39/44 0.88 (0.56-1.37) 45/49 0.93 (0.61-1.42) 54/54 1.02 (0.69-1.51) 30/39 0.75 (0.46-1.24) 
p-trend    0.77   0.75   0.92   0.78   0.41 
per G allele -30  0.96 (0.72-1.28)  0.93 (0.61-1.42)  0.98 (0.66-1.45)  1.05 (0.73-1.53)  0.82 (0.52-1.31) 
rs1130864                 
GG 0 315/346 1.00 (Ref.) 154/154 1.00 (Ref.) 161/192 1.00 (Ref.) 209/226 1.00 (Ref.) 106/120 1.00 (Ref.) 
GA/AA 13 405/379 1.17 (0.94-1.44) 174/175 0.97 (0.71-1.34) 231/204 1.35 (1.01-1.79) 271/257 1.14 (0.88-1.49) 134/122 1.21 (0.84-1.74) 
p-trend    0.04   0.42   0.04   0.14   0.14 
per A allele 15  1.19 (1.01-1.40)  1.10 (0.87-1.41)  1.26 (1.01-1.57)  1.16 (0.95-1.41)  1.25 (0.93-1.67) 
rs2808630                 
TT 0 370/386 1.00 (Ref.) 171/175 1.00 (Ref.) 199/211 1.00 (Ref.) 245/265 1.00 (Ref.) 125/121 1.00 (Ref.) 
CT -18 279/279 1.04 (0.84-1.29) 125/131 0.99 (0.72-1.35) 154/148 1.09 (0.81-1.47) 186/181 1.10 (0.85-1.44) 93/98 0.93 (0.64-1.36) 
CC 12 70/58 1.26 (0.86-1.85) 32/23 1.45 (0.83-2.52) 38/35 1.11 (0.65-1.89) 48/35 1.53 (0.95-2.46) 22/23 0.88 (0.46-1.68) 
32 
 
p-trend    0.30   0.38   0.54   0.10   0.63 
per C allele -30  1.09 (0.93-1.27)  1.11 (0.88-1.39)  1.07 (0.86-1.33)  1.18 (0.97-1.43)  0.94 (0.71-1.23) 
rs3093077                 
AA 0 634/621 1.00 (Ref.) 288/285 1.00 (Ref.) 346/336 1.00 (Ref.) 418/412 1.00 (Ref.) 216/209 1.00 (Ref.) 
AC/CC 29 87/101 0.84 (0.62-1.15) 41/41 0.97 (0.60-1.57) 46/60 0.76 (0.51-1.14) 62/70 0.86 (0.59-1.26) 25/31 0.79 (0.46-1.37) 
p-trend    0.29   0.90   0.21   0.47   0.41 
per C allele 32  0.85 (0.63-1.15)  0.97 (0.60-1.57)  0.78 (0.53-1.15)  0.88 (0.61-1.25)  0.79 (0.46-1.37) 
unweighted CRP-score                 
0 or 1 or 2  0 93/104 1.00 (Ref.) 48/44 1.00 (Ref.) 45/60 1.00 (Ref.) 54/67 1.00 (Ref.) 39/37 1.00 (Ref.) 
3,4 23 342/379 1.02 (0.75-1.39) 154/181 0.84 (0.54-1.31) 188/198 1.26 (0.81-1.96) 233/251 1.17 (0.79-1.73) 109/128 0.83 (0.50-1.37) 
5 25 165/153 1.20 (0.84-1.70) 71/68 1.01 (0.60-1.70) 94/85 1.43 (0.88-2.33) 108/100 1.34 (0.86-2.11) 57/53 1.01 (0.57-1.77) 
6 or 7  46 121/90 1.50 (1.01-2.22) 56/37 1.39 (0.77-2.50) 65/53 1.62 (0.94-2.76) 85/65 1.63 (1.01-2.65) 36/25 1.32 (0.66-2.66) 
p-trend    0.02   0.12   0.06   0.03   0.28 
per score unit  13  1.08 (1.00-1.17)  1.08 (0.96-1.22)  1.09 (0.98-1.21)  1.10 (1.00-1.21)  1.06 (0.93-1.21) 
weighted CRP-score                 
Tertile 1 0 226/261 1.00 (Ref.) 111/124 1.00 (Ref.) 115/137 1.00 (Ref.) 144/166 1.00 (Ref.) 82/95 1.00 (Ref.) 
Tertile 2 23 187/190 1.14 (0.86-1.49) 79/86 1.05 (0.70-1.58) 108/104 1.21 (0.84-1.75) 127/128 1.16 (0.83-1.62) 60/62 1.09 (0.68-1.75) 
Tertile 3 33 308/275 1.27 (1.00-1.62) 139/120 1.28 (0.89-1.84) 169/155 1.26 (0.91-1.75) 209/189 1.27 (0.94-1.72) 99/86 1.27 (0.84-1.92) 
p-trend    0.05   0.17   0.17   0.12   0.25 
per score unit 65  1.15 (0.99-1.35)  1.20 (0.95-1.52)  1.11 (0.90-1.37)  1.17 (0.96-1.42)  1.12 (0.86-1.46) 
a based on unadjusted mixed model  
OR, odds ratio; models were conditional logistic regression models, controlled for matching factors, without further adjustment 
 
Supplemental Table 1a. Baseline characteristics by CRP-SNPs rs1205 and rs1800947 in control participants (n=727) 
  rs1205   rs1800947     
  CC (n=302) CT (n=342) TT (n=81) p-value CC (n=633) CG/GG (n=93) p-value 
Female sex, n (%) 173 (57.3) 177 (51.8) 46 (56.8) 0.34 347 (54.8) 49 (52.7) 0.70 
Age, years, mean (SD) 58.9 (7.9) 59.1 (7.8) 58.6 (8.5) 0.85 58.9 (8.0) 59.3 (7.0) 0.63 
Current smoking, n (%) 58 (19.2) 71 (20.8) 21 (25.9) 0.41 124 (19.6) 26 (28.0) 0.06 
University degree, n (%) 48 (15.9) 58 (17.0) 12 (14.8) 0.87 105 (16.6) 13 (14.0) 0.52 
Physically inactive, n (%) 35 (11.6) 36 (10.5) 4 (4.9) 0.22 69 (10.9) 6 (6.5) 0.19 
Height, cm, mean (SD) 166 (8.9) 166 (9.0) 166 (9.0) 0.67 166 (9.0) 166 (8.8) 0.80 
Body mass index, kg/m2, mean (SD) 26.3 (3.8) 26.4 (3.7) 27.0 (3.9) 0.17 26.4 (3.8) 26.6 (3.8) 0.61 
Waist circumference, cm, mean (SD) 88.1 (12.4) 88.6 (11.7) 89.8 (11.0) 0.30 88.5 (11.9) 89.1 (12.0) 0.64 
Alcohol intake, g/day, mean (SD) 12.8 (17.8) 12.9 (18.9) 10.7 (16.6) 0.53 12.8 (18.6) 11.7 (15.7) 0.58 
Fiber, g/day, mean (SD) 23.0 (7.7) 23.0 (8.0) 21.5 (6.7) 0.22 22.8 (7.8) 23.4 (7.3) 0.51 
Energy, kcal/day, mean (SD) 2059 (601) 2074 (677) 1963 (508) 0.45 2056 (609) 2064 (764) 0.91 
Fruits and vegetables, g/day, mean (SD) 448 (266) 446 (267) 432 (244) 0.68 443 (261) 460 (286) 0.56 
Red and processed meat, g/day, mean (SD) 76.2 (46.8) 77.8 (44.4) 76.9 (47.0) 0.76 77.2 (45.0) 76.4 (50.3) 0.87 
Fish, g/day, mean (SD) 30.2 (30.9) 31.0 (30.5) 30.3 (27.9) 0.87 29.6 (29.4) 37.0 (35.6) 0.03 
CRP, mg/L, median (IQR) 2.62 (1.35- 5.03) 2.12 (0.96- 4.17) 1.76 (0.83- 3.73) 0.003 2.42 (1.11- 4.63) 1.65 (0.80- 3.38) 0.01 
C-peptide (ng/mL), median (IQR) 3.54 (2.60- 5.15) 3.41 (2.69- 5.10) 3.58 (2.73- 4.62) 0.96 3.51 (2.65- 5.05) 3.44 (2.76- 5.10) 0.98 
HbA1c (%), median (IQR) 5.70 (5.50- 6.10) 5.70 (5.50- 6.00) 5.70 (5.50- 6.00) 0.81 5.70 (5.50- 6.00) 5.70 (5.60- 6.10) 0.66 
IGF1 (ng/mL), median (IQR) 214.8 (165.5-274.2) 214.5 (175.8-261.9) 193.1 (173.2-241.9) 0.68 213.8 (170.7-261.6) 205.9 (169.8-273.2) 0.70 
Total cholesterol (mmol/L), median (IQR) 6.45 (5.66- 7.25) 6.31 (5.57- 7.15) 6.49 (5.74- 7.05) 0.41 6.39 (5.60- 7.22) 6.37 (5.63- 7.02) 0.82 
LDL cholesterol (mmol/L), median (IQR) 4.45 (3.82- 5.28) 4.31 (3.67- 5.02) 4.28 (3.66- 5.00) 0.14 4.36 (3.70- 5.18) 4.33 (3.70- 5.00) 0.77 
HDL cholesterol (mmol/L), median (IQR) 1.36 (1.15- 1.61) 1.34 (1.13- 1.62) 1.27 (1.09- 1.54) 0.31 1.35 (1.14- 1.61) 1.31 (1.07- 1.65) 0.71 
Triglycerides (mmol/L), median (IQR) 1.40 (0.98- 1.92) 1.40 (0.94- 1.99) 1.42 (0.94- 2.42) 0.50 1.41 (0.97- 2.00) 1.30 (0.88- 1.97) 0.50 
Total adiponectin (μg/mL), median (IQR) 6.68 (4.98- 9.17) 6.51 (4.90- 8.96) 6.05 (4.65- 9.15) 0.66 6.63 (4.93- 8.99) 6.21 (4.76- 9.09) 0.52 
HMW adiponectin (µg/mL), median (IQR) 3.45 (2.31- 5.11) 3.16 (2.11- 4.91) 3.29 (2.12- 4.87) 0.69 3.34 (2.21- 4.98) 3.29 (2.00- 5.07) 0.59 
Leptin (ng/mL), median (IQR) 9.25 (4.31-20.10) 8.97 (4.01-18.50) 11.30 (4.86-22.50) 0.57 9.44 (4.44-19.80) 8.03 (3.78-17.25) 0.28 
Soluble Leptin Receptor (ng/mL), median (IQR) 21.20 (17.60-26.50) 21.90 (17.80-26.55) 19.65 (16.70-24.30) 0.05 21.20 (17.60-26.40) 21.60 (18.00-26.50) 0.67 
25-hydroxy vitamin D (nmol/L), median (IQR) 61.05 (45.90-79.00) 58.50 (41.90-77.60) 55.00 (44.30-72.30) 0.25 59.50 (44.00-78.10) 57.20 (45.90-76.90) 0.80 
 SD, standard deviation; IQR, inter-quartile range ; CRP, C-reactive protein; , HbA1c, glycated hemoglobin; LDL, low density lipoprotein cholesterol; HDL, high 
density lipoprotein cholesterol; HMW, high-molecular weight 
P-values were determined by Chi-Square test for categorical variables, by analysis of variance for variables expressed as means, and by Kruskal-Wallis test for 
variables expressed as medians 
Supplemental Table 1b. Baseline characteristics by CRP-SNPs rs1130864 and rs2808630 in control participants (n=727) 
  rs1130864   rs2808630   
  
GG (n=346) GA (n=317) AA (n=62) 
p-
value* TT (n=386) CT (n=279) CC (n=58) p-value 
Female sex, n (%) 192 (55.5) 168 (53.0) 36 (58.1) 0.69 211 (54.7) 148 (53.0) 35 (60.3) 0.59 
Age, years, mean (SD) 58.9 (8.0) 58.7 (7.8) 59.9 (8.2) 0.65 58.9 (7.8) 58.6 (8.0) 60.4 (8.0) 0.58 
Current smoking, n (%) 70 (20.2) 69 (21.8) 11 (17.7) 0.74 80 (20.7) 61 (21.9) 9 (15.5) 0.56 
University degree, n (%) 60 (17.3) 49 (15.5) 9 (14.5) 0.75 63 (16.3) 44 (15.8) 11 (19.0) 0.84 
Physically inactive, n (%) 31 (9.0) 39 (12.3) 5 (8.1) 0.31 37 (9.6) 31 (11.1) 7 (12.1) 0.74 
Height, cm, mean (SD) 166 (9.1) 166 (8.8) 166 (9.0) 0.58 166 (8.7) 166 (9.4) 165 (8.4) 0.64 
Body mass index, kg/m2, mean (SD) 26.5 (3.7) 26.4 (3.9) 26.3 (3.5) 0.78 26.5 (3.7) 26.3 (4.0) 26.1 (3.0) 0.31 
Waist circumference, cm, mean (SD) 88.5 (11.4) 88.6 (12.5) 88.5 (11.8) 0.92 88.7 (11.5) 88.3 (12.7) 88.1 (10.5) 0.64 
Alcohol intake, g/day, mean (SD) 11.7 (17.2) 13.3 (18.4) 14.6 (22.9) 0.16 13.1 (19.2) 12.6 (18.0) 11.3 (12.8) 0.50 
Fiber, g/day, mean (SD) 22.7 (7.6) 23.2 (8.1) 21.9 (6.7) 0.89 22.6 (7.6) 23.0 (8.0) 24.2 (7.6) 0.14 
Energy, kcal/day, mean (SD) 2015 (606) 2107 (670) 2045 (555) 0.20 2055 (614) 2068 (679) 2036 (501) 0.99 
Fruits and vegetables, g/day, mean (SD) 435 (262) 453 (257) 461 (312) 0.33 457 (267) 427 (262) 460 (247) 0.43 
Red and processed meat, g/day, mean (SD) 75.4 (42.4) 78.3 (48.7) 81.0 (47.8) 0.29 79.0 (46.1) 76.1 (46.4) 70.6 (38.9) 0.17 
Fish, g/day, mean (SD) 29.7 (30.2) 31.1 (30.2) 33.0 (32.7) 0.40 31.1 (29.4) 31.1 (32.8) 24.3 (23.5) 0.28 
CRP, mg/L, median (IQR) 2.05 (1.01- 3.91) 2.33 (1.05- 4.74) 2.65 (1.60- 4.75) 0.05 2.39 (1.11- 4.62) 2.01 (0.93- 3.82) 2.87 (1.36- 5.15) 0.06 
C-peptide (ng/mL), median (IQR) 3.38 (2.65- 5.09) 3.52 (2.64- 5.00) 3.70 (2.79- 4.38) 0.91 3.60 (2.72- 5.09) 3.25 (2.57- 4.80) 3.94 (2.51- 5.79) 0.24 
HbA1c (%), median (IQR) 5.70 (5.50- 5.90) 5.80 (5.60- 6.10) 5.70 (5.40- 6.00) 0.06 5.80 (5.50- 6.00) 5.70 (5.50- 6.00) 5.70 (5.50- 6.05) 0.35 
IGF1 (ng/mL), median (IQR) 209.3 (171.6-259.2) 214.5 (167.2-
269.0) 
210.3 (178.5-
284.7) 
0.91 211.0 (173.2-262.1) 214.3 (169.8-
264.7) 
212.9 (156.7-
253.5) 
0.82 
Total cholesterol (mmol/L), median (IQR) 6.39 (5.60- 7.04) 6.39 (5.67- 7.33) 6.34 (5.47- 7.15) 0.56 6.34 (5.58- 7.13) 6.41 (5.59- 7.34) 6.66 (5.76- 7.22) 0.36 
LDL cholesterol (mmol/L), median (IQR) 4.34 (3.64- 5.08) 4.39 (3.80- 5.22) 4.28 (3.89- 5.14) 0.49 4.26 (3.70- 5.03) 4.44 (3.69- 5.22) 4.67 (4.05- 5.37) 0.11 
HDL cholesterol (mmol/L), median (IQR) 1.33 (1.17- 1.61) 1.36 (1.13- 1.63) 1.31 (1.08- 1.56) 0.42 1.33 (1.11- 1.59) 1.38 (1.17- 1.62) 1.34 (1.18- 1.61) 0.26 
Triglycerides (mmol/L), median (IQR) 1.40 (0.95- 2.05) 1.42 (0.96- 2.00) 1.40 (0.99- 1.77) 0.86 1.40 (0.96- 1.99) 1.40 (0.95- 2.02) 1.48 (1.01- 2.02) 0.83 
Total adiponectin (μg/mL), median (IQR) 6.65 (4.96- 9.15) 6.46 (4.80- 8.84) 6.97 (5.47- 8.82) 0.41 6.43 (4.87- 8.91) 6.70 (4.96- 9.09) 6.19 (4.83- 8.95) 0.56 
HMW adiponectin (µg/mL), median (IQR) 3.29 (2.15- 5.03) 3.23 (2.06- 4.87) 3.59 (2.57- 5.15) 0.26 3.29 (2.13- 4.88) 3.36 (2.26- 5.07) 3.18 (2.04- 4.56) 0.59 
Leptin (ng/mL), median (IQR) 9.74 (4.47-21.70) 9.00 (3.94-18.50) 9.71 (5.23-18.20) 0.67 9.44 (4.50-20.10) 9.10 (4.12-18.10) 9.06 (3.71-24.10) 0.71 
Soluble Leptin Receptor (ng/mL), median (IQR) 21.00 (17.80-26.20) 21.80 (17.60-
26.70) 
21.10 (15.80-
27.00) 
0.70 21.00 (17.20-25.80) 22.10 (18.00-
26.50) 
20.75 (17.60-
26.50) 
0.22 
25-hydroxy vitamin D (nmol/L), median (IQR) 57.60 (43.80-75.10) 60.85 (43.50-
79.85) 
61.40 (47.30-
81.60) 
0.49 58.00 (42.10-78.50) 58.90 (46.40-
75.50) 
63.65 (46.30-
80.80) 
0.28 
SD, standard deviation; IQR, inter-quartile range; CRP, C-reactive protein; , HbA1c, glycated hemoglobin; LDL, low density lipoprotein cholesterol; HDL, high 
density lipoprotein cholesterol; HMW, high-molecular weight 
P-values were determined by Chi-Square test for categorical variables, by analysis of variance for variables expressed as means, and by Kruskal-Wallis test for 
variables expressed as medians 
  
Supplemental Table 1c. Baseline characteristics by CRP-SNPs rs3093077 (n=727) 
  
rs3093077 
  
  
AA (n=621) AC/CC (n=101) p-value 
Female sex, n (%) 336 (54.1) 60 (59.4) 0.32 
Age, years, mean (SD) 59.1 (8.1) 58.1 (6.7) 0.23 
Current smoking, n (%) 134 (21.6) 16 (15.8) 0.19 
University degree, n (%) 95 (15.3) 21 (20.8) 0.16 
Physically inactive, n (%) 62 (10.0) 12 (11.9) 0.56 
Height, cm, mean (SD) 166 (9.0) 165 (8.5) 0.53 
Body mass index, kg/m2, mean (SD) 26.5 (3.7) 26.1 (4.1) 0.35 
Waist circumference, cm, mean (SD) 88.8 (11.9) 86.6 (11.9) 0.10 
Alcohol intake, g/day, mean (SD) 13.0 (18.7) 11.5 (15.7) 0.45 
Fiber, g/day, mean (SD) 22.9 (7.8) 22.5 (7.6) 0.59 
Energy, kcal/day, mean (SD) 2067 (638) 1987 (583) 0.24 
Fruits and vegetables, g/day, mean (SD) 445 (264) 450 (269) 0.87 
Red and processed meat, g/day, mean (SD) 77.3 (46.1) 75.2 (42.0) 0.68 
Fish, g/day, mean (SD) 30.6 (30.2) 30.2 (31.0) 0.90 
CRP, mg/L, median (IQR) 2.15 (1.03- 4.17) 2.90 (1.52- 5.65) 0.003 
C-peptide (ng/mL), median (IQR) 3.52 (2.68- 5.01) 3.28 (2.67- 5.28) 0.92 
HbA1c (%), median (IQR) 5.70 (5.50- 6.00) 5.70 (5.50- 6.00) 0.67 
IGF1 (ng/mL), median (IQR) 209.0 (169.0-
264.7) 
231.9 (187.2-
260.9) 
0.22 
Total cholesterol (mmol/L), median (IQR) 6.39 (5.65- 7.25) 6.32 (5.55- 6.98) 0.11 
LDL cholesterol (mmol/L), median (IQR) 4.37 (3.71- 5.22) 4.17 (3.55- 4.86) 0.08 
HDL cholesterol (mmol/L), median (IQR) 1.34 (1.13- 1.62) 1.40 (1.19- 1.61) 0.23 
Triglycerides (mmol/L), median (IQR) 1.41 (0.96- 2.02) 1.14 (0.92- 1.78) 0.03 
Total adiponectin (μg/mL), median (IQR) 6.57 (4.90- 9.02) 6.87 (5.25- 9.01) 0.42 
HMW adiponectin (µg/mL), median (IQR) 3.29 (2.12- 4.99) 3.59 (2.40- 5.09) 0.47 
Leptin (ng/mL), median (IQR) 9.25 (4.24-19.05) 9.44 (4.71-21.70) 0.51 
Soluble Leptin Receptor (ng/mL), median (IQR) 21.50 (17.60-
26.50) 
21.10 (17.80-
26.20) 
0.97 
25-hydroxy vitamin D (nmol/L), median (IQR) 59.70 (44.50-
78.10) 
56.10 (39.70-
75.80) 
0.08 
SD, standard deviation; IQR, inter-quartile range ; CRP, C-reactive protein; , HbA1c, glycated hemoglobin; LDL, low density lipoprotein cholesterol; HDL, high 
density lipoprotein cholesterol; HMW, high-molecular weight 
P-values were determined by Chi-Square test for categorical variables, by analysis of variance for variables expressed as means, and by Kruskal-Wallis test for 
variables expressed as medians 
  
Supplemental Table 1d. Baseline characteristics by weighted and unweighted CRP-score in control participants (n=727) 
  Unweighted CRP-score  Weighted CRP-score  
  0,1, 2 (n=104) 3,4 (n=379) 5 (n=153) 6, 7 (n=90) 
p-
value Tertile 1 Tertile 2 Tertile 3 p-value 
Female sex, n (%) 60 (57.7) 198 (52.2) 85 (55.6) 53 (58.9) 0.58 137 (52.5) 104 (54.7) 155 (56.4) 0.67 
Age, years, mean (SD) 58.9 (8.4) 59.2 (7.8) 58.2 (8.0) 59.3 (7.6) 0.80 58.8 ( 7.9) 59.6 ( 8.1) 58.6 ( 7.8) 0.75 
Current smoking, n (%) 27 (26.0) 74 (19.5) 33 (21.6) 16 (17.8) 0.46 62 (23.8) 32 (16.8) 56 (20.4) 0.20 
University degree, n (%) 15 (14.4) 66 (17.4) 21 (13.7) 16 (17.8) 0.68 43 (16.5) 30 (15.8) 45 (16.4) 0.98 
Physically inactive, n (%) 4 (3.8) 43 (11.3) 18 (11.8) 10 (11.1) 0.14 23 ( 8.8) 19 (10.0) 33 (12.0) 0.47 
Height, cm, mean (SD) 165 (9.2) 166 (8.8) 166 (9.0) 166 (9.0) 0.76 166 ( 9.3) 166 ( 8.5) 166 ( 8.9) 0.51 
Body mass index, kg/m2, mean (SD) 26.9 (4.0) 26.4 (3.5) 26.3 (4.2) 26.2 (3.7) 0.21 26.6 ( 3.8) 26.4 ( 3.5) 26.3 ( 3.9) 0.39 
Waist circumference, cm, mean (SD) 89.3 (11.5) 88.7 (11.4) 87.9 (13.3) 88.1 (11.9) 0.39 89.2 (11.6) 88.5 (11.6) 88.0 (12.4) 0.23 
Alcohol intake, g/day, mean (SD) 11.5 (17.4) 12.7 (18.2) 13.2 (18.1) 13.4 (20.1) 0.45 12.1 (17.5) 12.7 (18.0) 13.3 (19.2) 0.46 
Fiber, g/day, mean (SD) 22.1 (7.1) 23.2 (7.9) 23.3 (8.2) 21.8 (7.0) 0.82 22.4 ( 7.4) 23.8 ( 8.4) 22.6 ( 7.6) 0.75 
Energy, kcal/day, mean (SD) 1999 (681) 2072 (620) 2082 (660) 2022 (565) 0.81 2035 ( 638) 2080 ( 632) 2062 ( 625) 0.62 
Fruits and vegetables, g/day, mean (SD) 435 (256) 448 (262) 451 (260) 437 (292) 0.95 425 ( 262) 472 ( 261) 446 ( 267) 0.36 
Red and processed meat, g/day, mean (SD) 74.0 (45.1) 77.7 (43.9) 76.3 (50.9) 79.4 (44.7) 0.56 77.4 (44.3) 76.5 (45.2) 77.2 (47.3) 0.97 
Fish, g/day, mean (SD) 30.6 (29.6) 30.2 (29.6) 32.9 (33.6) 28.4 (28.8) 0.95 31.8 (31.3) 27.9 (27.9) 31.2 (31.1) 0.84 
CRP, mg/L, median (IQR) 1.85 (0.82- 3.44) 2.19 (1.04- 4.45) 2.33 (1.09- 4.89) 2.91 (1.66- 5.40) 0.0008 1.84 ( 0.83- 3.65) 2.39 ( 1.11- 4.74) 2.76 ( 1.41- 5.46) <0.0001 
C-peptide (ng/mL), median (IQR) 3.44 (2.62- 4.93) 3.52 (2.69- 5.21) 3.27 (2.53- 4.79) 3.71 (2.79- 5.60) 0.35 3.34 ( 2.70- 4.97) 3.74 ( 2.71- 5.60) 3.44 ( 2.59- 4.87) 0.35 
HbA1c (%), median (IQR) 5.70 (5.50- 5.90) 5.70 (5.50- 6.00) 5.70 (5.40- 6.00) 5.80 (5.40- 6.10) 0.75 5.70 ( 5.50- 6.00) 5.80 ( 5.50- 6.00) 5.70 ( 5.50- 6.00) 0.41 
IGF1 (ng/mL), median (IQR) 193.9 (172.5-
241.9) 
214.8 (170.7-
261.6) 
219.0 (165.9-
263.3) 
214.4 (173.4-
308.0) 0.68 
208.8 (174.0-
264.7) 
210.5 (163.9-
259.6) 
216.7 (167.6-
266.7) 
0.61 
Total cholesterol (mmol/L), median (IQR) 6.48 (5.69- 7.13) 6.32 (5.60- 7.15) 6.46 (5.68- 7.38) 6.36 (5.56- 7.08) 0.66 6.37 ( 5.61- 7.05) 6.37 ( 5.67- 7.25) 6.41 ( 5.57- 7.21) 0.70 
LDL cholesterol (mmol/L), median (IQR) 4.28 (3.67- 5.06) 4.35 (3.69- 5.12) 4.48 (3.75- 5.31) 4.27 (3.87- 5.11) 0.67 4.32 ( 3.66- 5.00) 4.49 ( 3.81- 5.29) 4.36 ( 3.75- 5.17) 0.35 
HDL cholesterol (mmol/L), median (IQR) 1.29 (1.14- 1.57) 1.34 (1.14- 1.62) 1.40 (1.20- 1.64) 1.31 (1.11- 1.56) 0.25 1.33 ( 1.13- 1.62) 1.34 ( 1.15- 1.62) 1.37 ( 1.15- 1.61) 0.61 
Triglycerides (mmol/L), median (IQR) 1.40 (0.93- 2.35) 1.41 (0.96- 2.01) 1.38 (0.95- 1.94) 1.42 (0.99- 1.78) 0.90 1.41 ( 0.93- 2.06) 1.44 ( 0.98- 2.04) 1.38 ( 0.97- 1.84) 0.60 
Total adiponectin (μg/mL), median (IQR) 6.55 (4.78- 9.19) 6.40 (4.89- 8.95) 6.67 (4.93- 9.32) 6.97 (5.35- 8.71) 0.61 6.65 ( 4.85- 9.08) 6.37 ( 4.80- 8.97) 6.79 ( 5.05- 8.84) 0.38 
HMW adiponectin (µg/mL), median (IQR) 3.29 (2.08- 5.01) 3.14 (2.09- 4.87) 3.55 (2.42- 5.04) 3.50 (2.38- 5.14) 0.50 3.30 ( 2.10- 5.03) 3.12 ( 2.06- 4.67) 3.48 ( 2.36- 5.04) 0.28 
Leptin (ng/mL), median (IQR) 10.15 (4.67-20.90) 9.02 (4.08-19.90) 
9.24 (4.31-
18.10) 
10.55 (4.60-
20.80) 0.83 9.70 ( 4.24-20.10) 8.26 ( 3.71-19.40) 
9.26 ( 4.44-
19.80) 
0.82 
Soluble Leptin Receptor (ng/mL), median 
(IQR) 
20.15 (16.80-
25.20) 
21.65 (17.70-
26.50) 
22.10 (18.30-
26.50) 
20.40 (16.40-
26.30) 0.20 
20.90 (17.70-
25.70) 
21.70 (17.30-
26.95) 
21.65 (17.80-
26.40) 
0.71 
25-hydrxoy vitamin D (nmol/L), median (IQR) 55.15 (44.50-
72.40) 
59.70 (42.50-
77.80) 
59.20 (44.90-
78.35) 
61.50 (46.70-
81.60) 0.63 
57.70 (44.30-
75.00) 
61.00 (42.10-
78.80) 
59.60 (44.50-
78.80) 
0.93 
SD, standard deviation; IQR, inter-quartile range ; CRP, C-reactive protein; , HbA1c, glycated hemoglobin; LDL, low density lipoprotein cholesterol; HDL, high 
density lipoprotein cholesterol; HMW, high-molecular weight 
P-values were determined by Chi-Square test for categorical variables, by analysis of variance for variables expressed as means, and by Kruskal-Wallis test for 
variables expressed as medians 
  
  
Supplemental Table 2 Percent difference in CRP associated with frequent CRP haplotypes in controls (n=727) 
 
CRP haplotypes Estimated frequency (SE) % difference in plasma CRP (mg/L) 95% CI 
C-G-C-T-C 0.07 (0.005) 0.0 (Reference) 
C-G-C-C-A 0.28 (0.008) -71.5 (-116.7, -26.3) 
C-G-T-T-A 0.26 (0.008) -85.0 (-130.7, -39.4) 
C-A-C-T-A 0.32 (0.009) -44.6 (-89.3, 0.1) 
G-G-T-T-A 0.06 (0.005) -128.3 (-188.8, -67.7) 
rare haplotypes  -168.2 (-298.9, -37.4) 
Models were unadjusted.  
Haplotype frequencies were estimated from the CRP SNPs rs1800947, rs1130864, rs1205, rs2808630 and rs3093077. 
 
 
  
Supplemental Table 3 Association between frequent CRP haplotypes and risk of colorectal cancer (n=1,454) 
   Colorectal cancer Men Women Colon cancer Rectal cancer 
 No. of cases/controls 727/727 331/331 393/393 483/483 244/244 
 CRP haplotypes % difference in 
CRPa 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
C-G-C-T-C 0.0 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
C-G-C-C-A -71.5 1.10 (0.60, 2.01) 0.97 (0.39, 2.45) 1.18 (0.53, 2.63) 1.16 (0.55, 2.44) 0.96 (0.34, 2.74) 
C-G-T-T-A -85.0 0.71 (0.38, 1.30) 0.63 (0.24, 1.65) 0.76 (0.34, 1.68) 0.57 (0.27, 1.23) 1.00 (0.36, 2.83) 
C-A-C-T-A -44.6 1.30 (0.71, 2.37) 1.04 (0.41, 2.64) 1.55 (0.71, 3.42) 1.20 (0.57, 2.53) 1.48 (0.53, 4.14) 
G-G-T-T-A -128.3 0.95 (0.43, 2.11) 0.76 (0.22, 2.62) 1.14 (0.40, 3.27) 1.06 (0.39, 2.91) 0.77 (0.21, 2.88) 
 rare haplotypes -168.2 2.58 (0.48, 13.94) 9.92 (0.64, 154.28) 0.76 (0.08, 7.71) 2.22 (0.32, 15.21) 4.21 (0.12, 152.73) 
a based on unadjusted mixed model 
OR, odds ratio; models were conditional logistic regression models, controlled for matching factors, without further adjustment. 
Supplemental Figure 1. Estimates of the association of circulating (observational) and genetically 
raised (instrumental variable analysis) CRP levels with risk of colorectal cancer by sex and 
cancer subsites 
† Observational OR (95% CI) from conditional logistic regression adjusted for smoking status 
(never, former, current or missing data), education (no school degree/primary school, 
technical/professional school, secondary school, university degree, or missing data), alcohol 
consumption (nondrinker or g/day), and physical activity (inactive, moderately inactive, 
moderately active, active, or missing data), body mass index and waist circumference 
‡ Instrumental variable analysis by 2-stage least-squares regression, adjusted for matching factors 
F-values (indicator of instrument strength) derived from first-stage regression.  
rs2808630 not displayed because of insufficient instrument strength (F-value=0.46) 
*OR per 2-fold higher CRP concentration on the original scale corresponds to a difference in log-
transformed CRP concentrations of log 2. 
 
 

